Centene (NYSE:CNC) FY Conference Transcript

Centene (NYSE:CNC) FY Conference Summary Company Overview - Company: Centene Corporation - Event: Barclays Global Healthcare Conference - Date: March 10, 2026 Key Points Current Business Performance - Centene reaffirms adjusted EPS guidance of greater than $3 for 2026, with all three core business lines (Medicaid, Medicare, and Marketplace) on track so far [4][8] - Medicaid membership is expected to be approximately 3.5 million by the end of Q1 2026, down from 5.5 million in December 2025 [5][10] - The company is optimistic about the execution of ongoing trend initiatives impacting Medicaid and Medicare [4][8] Marketplace Dynamics - Membership in the Marketplace has decreased from 5.5 million in December to 3.6 million in February 2026, with expectations of reaching around 3.5 million by the end of the quarter [5][10] - The distribution of metal tiers shows a shift, with mid-30s% in Bronze, high teens% in Gold, and just under 50% in Silver [6][11] - Higher utilization patterns in specialty pharmacy are noted, particularly in the Silver tier, which may impact risk adjustment calculations [6][17] Risk Adjustment and Data Insights - Centene is tracking a Wakely report due at the end of March, which will provide insights into market contraction and membership distribution across metal tiers [7][13] - The company anticipates being in a net payable position for risk adjustment in 2026, but will remain conservative until full data is available [13][16] - The focus is on understanding therapeutic classes and disease states to inform risk adjustment strategies [17][18] Medicaid Trends and Initiatives - Medicaid cost trend for 2026 is expected to be around 4.5%, down from mid-6% in 2025 [19][20] - Centene is actively working on initiatives to combat fraud, waste, and abuse, which is estimated to account for 10% of all healthcare spending [22][23] - The company has developed 75 algorithms to identify suspect claims and is enhancing data sharing with state partners to improve program integrity [22][25] Medicare and Part D Insights - The individual PDP industry growth is expected to accelerate from 1% in 2025 to close to 3% in 2026, with Centene taking market share [31] - The company aims for a Part D margin of around 2% for 2026, with a focus on maintaining a favorable cost structure [32][33] - Medicare Advantage margins are projected to be slightly below break-even in 2026, with a goal of achieving break-even by 2027 [35][36] Capital Deployment Strategy - Centene plans no share repurchase in 2026, focusing instead on a partial redemption of $1 billion of 2027 notes to recalibrate debt levels [39][40] - The company is exploring ways to generate cash and monetize assets as part of its capital deployment strategy [40] Future Outlook on Medicaid Policy - Membership levels in Medicaid are expected to decline slightly due to tighter eligibility verification processes [41][42] - The impact of OB3 and work requirements will be assessed on a state-by-state basis, with guidance from CMS expected to influence future membership and margins [44][46] Additional Insights - The dialogue with CMS regarding Medicare rates has focused on ensuring that trend assumptions are reflective of current realities, particularly in light of COVID-19 data [36][37] - Centene is preparing for potential shifts in risk pools due to changes in Medicaid rates and eligibility requirements [46] This summary encapsulates the key insights and strategic directions discussed during the conference, highlighting Centene's performance, market dynamics, and future outlook in the healthcare sector.